Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | MTOR | P42345 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30630511 | 1.00 | CYP4F2 (0.39) | CYP4F2CYP4A11STSPIK3CAMTOR | |
| SCHEMBL24424190 | 1.00 | CYP4F2 (0.39) | CYP4F2CYP4A11STSPIK3CAMTOR | |
| SCHEMBL30630698 | 0.91 | CYP4F2 (0.36) | CYP4F2CYP4A11STSPIK3CAMTOR | |
| SCHEMBL25090842 | 0.91 | CYP4F2 (0.36) | CYP4F2CYP4A11STSPIK3CAMTOR | |
| SCHEMBL29585274 | 0.91 | CYP4F2 (0.36) | CYP4F2CYP4A11STSPIK3CAMTOR | |
| SCHEMBL29243764 | 0.84 | CYP4F2 (0.38) | CYP4F2CYP4A11KDM5A | |
| SCHEMBL24424213 | 0.84 | CYP4F2 (0.38) | CYP4F2CYP4A11KDM5A | |
| SCHEMBL30298765 | 0.84 | CYP4F2 (0.38) | CYP4F2CYP4A11KDM5A | |
| SCHEMBL29584356 | 0.84 | CYP4F2 (0.38) | CYP4F2CYP4A11KDM5A | |
| SCHEMBL24423931 | 0.84 | CYP4F2 (0.38) | CYP4F2CYP4A11STSPIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| EP-4240736-A1 | PPAR GAMMA MODULATORS AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2023-09-13 | — | — | EP | disclosed |
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-03-02 | — | — | US | disclosed |
| WO-2022099144-A1 | ΡΡΑRγ MODULATORS AND METHODS OF USE | Eisai R&D Mangement Co., Ltd. (JP) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | PPARG, PPARA, PPARD | CYP4F2 290/4885CYP4A11 75/4885STS 2646/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | CYP4F2 523/4885CYP4A11 88/4885STS 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.